Goldman Sachs reiterates Conviction Buy rating on Johnson & Johnson stock

Goldman Sachs has reiterated its "Conviction Buy" rating on Johnson & Johnson (JNJ) with a $177 price target, anticipating Q2 earnings largely in line with consensus but projecting stronger performance from key Innovative Medicine products like Carvykti and Tremfya. The firm emphasizes the Innovative Medicine segment's significance for stock performance, noting JNJ's 8% year-to-date outperformance in U.S. pharmaceuticals despite ongoing talc litigation concerns. Goldman views JNJ as a potential defensive play, benefiting from positive earnings revisions and a potential Fed rate-cutting cycle.

Analysis

Goldman Sachs has reiterated its "Conviction Buy" rating on Johnson & Johnson (JNJ) with a $177 price target, signaling strong confidence ahead of the Q2 earnings report. The firm's thesis hinges on the performance of the Innovative Medicine segment, which drives 83% of profit and is expected to outperform consensus estimates, led by key products Carvykti (+10% vs. consensus) and Tremfya (+2% vs. consensus). This segment's trajectory is presented as more critical to valuation than the MedTech division. Despite JNJ's strong year-to-date stock performance, up 8% while the NYSE Arca Pharmaceutical Index remained flat, a significant risk overhang exists from the ongoing talc litigation, with updates expected in the fall. The positive outlook is further supported by a series of promising clinical developments, including a new FDA submission for CAPLYTA in schizophrenia, sustained efficacy data for IMAAVY, high response rates for an experimental CAR T-cell therapy, and positive combination study results for its leukemia drug bleximenib. These pipeline advancements reinforce the fundamental strength in the core Innovative Medicine business. Furthermore, Goldman notes that JNJ's positive earnings and sales revisions position it as a defensive stock that could attract investment flows in a potential Federal Reserve rate-cutting cycle.

Key Decisions for Investors

• Investors should view the upcoming July 16 earnings report as a key catalyst, focusing on the revenue growth within the Innovative Medicine segment to validate the bullish thesis.
• Monitor news flow regarding the talc litigation closely, as any negative developments in the fall could create a significant headwind for the stock, potentially offsetting positive operational performance.
• Given JNJ's market outperformance and strong pipeline, it warrants consideration as a core defensive holding in the pharmaceutical sector, particularly for those anticipating a more accommodative monetary policy environment.
• The performance of high-growth drugs Carvykti and Tremfya should be scrutinized in the Q2 results, as they are pivotal to meeting or exceeding the optimistic projections set by analysts.